Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

MYGN POWR Grades

• Value is the dimension where MYGN ranks best; there it ranks ahead of 75.85% of US stocks.
• The strongest trend for MYGN is in Growth, which has been heading down over the past 177 days.
• MYGN ranks lowest in Momentum; there it ranks in the 4th percentile.

MYGN Stock Summary

• MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 125.6 -- higher than 82.5% of US-listed equities with positive expected earnings growth.
• The ratio of debt to operating expenses for MYRIAD GENETICS INC is higher than it is for about only 18.53% of US stocks.
• With a year-over-year growth in debt of -49.83%, MYRIAD GENETICS INC's debt growth rate surpasses merely 6.2% of about US stocks.
• Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are NUVA, TCX, LPTH, ANGO, and SEMR.
• MYGN's SEC filings can be seen here. And to visit MYRIAD GENETICS INC's official web site, go to myriad.com.

MYGN Valuation Summary

• In comparison to the median Healthcare stock, MYGN's EV/EBIT ratio is 518.75% lower, now standing at -33.5.
• MYGN's price/earnings ratio has moved down 58.6 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

MYGN Growth Metrics

Its 2 year cash and equivalents growth rate is now at 36.53%.
• Its year over year revenue growth rate is now at 20.54%.
• Its 3 year cash and equivalents growth rate is now at 94.58%.

Over the past 33 months, MYGN's revenue has gone down $162,800,000.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	672.3	-146	-17.6
2022-03-31	682.4	-100.1	-8.2
2021-12-31	690.6	18.2	-27.2
2021-09-30	684.4	13.7	-57.5
2021-06-30	662.3	-6.3	-97.3
2021-03-31	566.1	28.1	-148

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
• MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
• CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.